Investegate |AstraZeneca PLC Announcements | AstraZeneca PLC: Update on US review of Fasenra in nasal polyps
Investegate announcements from AstraZeneca PLC, Update on US review of Fasenra in nasal polyps
Stay updated with breaking news from Emerging Endotypes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from AstraZeneca PLC, Update on US review of Fasenra in nasal polyps
Search jobs 16-Dec-2020 First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis New clinical trial also announced for Fasenra in eosinophilic gastritis/eosinophilic gastroenteritis The first patients have been dosed in Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinophilic esophagitis (EoE) and eosinophilic granulomatosis with polyangiitis (EGPA) AstraZeneca will al...